Latest News

How Environmental Pollutants and Genetics Work Together in Rheumatoid Arthritis
How Environmental Pollutants and Genetics Work Together in Rheumatoid Arthritis
News   Apr 20, 2018

It is well known that individuals with a particular version of human leukocyte antigen have an increased risk for rheumatoid arthritis, but there has been growing interest in the role of environmental pollutants. In a new mouse study, researchers probed the relationship between the two.

READ MORE

New Process to Differentiate Stem Cells into Nucleus Pulposus-Like Cells
New Process to Differentiate Stem Cells into Nucleus Pulposus-Like Cells
News   Apr 18, 2018

Researchers at Washington University have developed a new way to transform human induced pluripotent stem cells into nucleus pulposus cells, which are the chief component of intervertebral discs.

READ MORE

Deficiency of Innate Immune Adaptor TRIF Linked to Neurodegeneration
Deficiency of Innate Immune Adaptor TRIF Linked to Neurodegeneration
News   Apr 18, 2018

Research has revealed that deficiency of the innate immune adaptor TRIF, which is essential for certain Toll-like receptor signaling cascades, significantly shortened survival time of ALS mice.

READ MORE

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets
PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets
News   Apr 16, 2018

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

READ MORE

Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine Yields
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine Yields
News   Apr 16, 2018

Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.

READ MORE

‘Bad’ Antibodies Provide Crucial Protection Against Invading Microbes
‘Bad’ Antibodies Provide Crucial Protection Against Invading Microbes
News   Apr 13, 2018

In a world first, scientists have revealed how a population of 'bad' antibodies in the immune system - which are usually 'silenced' because they can harm the body - can provide crucial protection against invading microbes.

READ MORE

"Superplatelets" Could Help Make Trauma More Survivable
"Superplatelets" Could Help Make Trauma More Survivable
News   Apr 13, 2018

A University of British Columbia bioengineer has developed a potential strategy for endowing platelets with extra powers so they can rise to the occasion and continue coagulation.

READ MORE

Personalized Tumor Vaccine Shows Promise
Personalized Tumor Vaccine Shows Promise
News   Apr 12, 2018

A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response.

READ MORE

Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas
News   Apr 12, 2018

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

READ MORE

Researchers Receive >$2 Million to Eradicate Common Type of Leukemia
Researchers Receive >$2 Million to Eradicate Common Type of Leukemia
News   Apr 11, 2018

Christoph Rader, PhD, associate professor at the Florida campus of The Scripps Research Institute, has been awarded a $2.875 million, five-year grant from the National Cancer Institute to develop unique antibody-drug conjugates engineered to eradicate one of the most common forms of leukemia, chronic lymphocytic leukemia (CLL).

READ MORE